OBJECTIVES: Diabetes mellitus (DM) is associated with an increased risk of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), but the association between DM and GEP-NET survival is unknown. We evaluated disease characteristics and survival in individuals with DM and GEP-NETs. METHODS: Using the Surveillance, Epidemiology, and End Results registry linked to Medicare (SEER-Medicare) claims database, we examined sociodemographics, GEP-NET characteristics, and treatment in patients with and without DM before GEP-NET diagnosis. We compared survival using univariate and multivariate analyses. RESULTS: We identified 1858 individuals with GEP-NETs: 478 (25.7%) with DM and 1380 (74.3%) without. Significant differences in race (P = 0.002) were found between the DM and non-DM groups. Compared with individuals without DM, those with DM had more gastric (9.7% vs 14.9%), duodenal (6.5% vs 10.0%), and pancreatic (17.0% vs 21.8%), and less jejunal/ileal (18.1% vs 12.8%) NETs (P < 0.0001). Patients with DM had earlier stages (stage I, 37.0%; stage IV, 30.8%) than those without (stage I, 30.6%; stage IV, 36.4%; P = 0.0012). We found no difference in survival (multivariate hazard ratio, 0.97; 95% confidence interval, 0.76-1.23) between groups. CONCLUSIONS: Among patients with and without DM before GEP-NET diagnosis, we found differences in tumor location and stage, but not survival.
OBJECTIVES: Diabetes mellitus (DM) is associated with an increased risk of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), but the association between DM and GEP-NET survival is unknown. We evaluated disease characteristics and survival in individuals with DM and GEP-NETs. METHODS: Using the Surveillance, Epidemiology, and End Results registry linked to Medicare (SEER-Medicare) claims database, we examined sociodemographics, GEP-NET characteristics, and treatment in patients with and without DM before GEP-NET diagnosis. We compared survival using univariate and multivariate analyses. RESULTS: We identified 1858 individuals with GEP-NETs: 478 (25.7%) with DM and 1380 (74.3%) without. Significant differences in race (P = 0.002) were found between the DM and non-DM groups. Compared with individuals without DM, those with DM had more gastric (9.7% vs 14.9%), duodenal (6.5% vs 10.0%), and pancreatic (17.0% vs 21.8%), and less jejunal/ileal (18.1% vs 12.8%) NETs (P < 0.0001). Patients with DM had earlier stages (stage I, 37.0%; stage IV, 30.8%) than those without (stage I, 30.6%; stage IV, 36.4%; P = 0.0012). We found no difference in survival (multivariate hazard ratio, 0.97; 95% confidence interval, 0.76-1.23) between groups. CONCLUSIONS: Among patients with and without DM before GEP-NET diagnosis, we found differences in tumor location and stage, but not survival.
Authors: Sara Pusceddu; Claudio Vernieri; Massimo Di Maio; Riccardo Marconcini; Francesca Spada; Sara Massironi; Toni Ibrahim; Maria Pia Brizzi; Davide Campana; Antongiulio Faggiano; Dario Giuffrida; Maria Rinzivillo; Sara Cingarlini; Francesca Aroldi; Lorenzo Antonuzzo; Rossana Berardi; Laura Catena; Chiara De Divitiis; Paola Ermacora; Vittorio Perfetti; Annalisa Fontana; Paola Razzore; Carlo Carnaghi; Maria Vittoria Davì; Carolina Cauchi; Marilina Duro; Sergio Ricci; Nicola Fazio; Federica Cavalcoli; Alberto Bongiovanni; Anna La Salvia; Nicole Brighi; Annamaria Colao; Ivana Puliafito; Francesco Panzuto; Silvia Ortolani; Alberto Zaniboni; Francesco Di Costanzo; Mariangela Torniai; Emilio Bajetta; Salvatore Tafuto; Silvio Ken Garattini; Daniela Femia; Natalie Prinzi; Laura Concas; Giuseppe Lo Russo; Massimo Milione; Luca Giacomelli; Roberto Buzzoni; Gianfranco Delle Fave; Vincenzo Mazzaferro; Filippo de Braud Journal: Gastroenterology Date: 2018-04-13 Impact factor: 22.682
Authors: Ben Lawrence; Bjorn I Gustafsson; Anthony Chan; Bernhard Svejda; Mark Kidd; Irvin M Modlin Journal: Endocrinol Metab Clin North Am Date: 2011-03 Impact factor: 4.741
Authors: Edward Giovannucci; David M Harlan; Michael C Archer; Richard M Bergenstal; Susan M Gapstur; Laurel A Habel; Michael Pollak; Judith G Regensteiner; Douglas Yee Journal: Diabetes Care Date: 2010-07 Impact factor: 19.112
Authors: Manal M Hassan; Alexandria Phan; Donghui Li; Cecile G Dagohoy; Colleen Leary; James C Yao Journal: Int J Cancer Date: 2008-08-15 Impact factor: 7.396